Market Inference Overview -- ILMN Stock

Illumina logged a 0.5% change during today's morning session, and is now trading at a price of $160.3 per share. The S&P 500 index moved -0.0%. ILMN's trading volume is 124,924 compared to the stock's average volume of 1,516,293.

Illumina trades -25.12% away from its average analyst target price of $214.09 per share. The 19 analysts following the stock have set target prices ranging from $135.0 to $318.0, and on average have given Illumina a rating of hold.

Anyone interested in buying ILMN should be aware of the facts below:

  • Illumina has moved -22.0% over the last year, and the S&P 500 logged a change of 14.0%

  • Based on its trailing earnings per share of -27.14, Illumina has a trailing 12 month Price to Earnings (P/E) ratio of -5.9 while the S&P 500 average is 15.97

  • ILMN has a forward P/E ratio of 68.5 based on its forward 12 month price to earnings (EPS) of $2.34 per share

  • The company has a price to earnings growth (PEG) ratio of -29.34 — a number near or below 1 signifying that Illumina is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 3.86 compared to its sector average of 4.16

  • Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function.

  • Based in San Diego, the company has 11,500 full time employees and a market cap of $25.38 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.